AEZS (Mcap $67M) (Cash $46M) PDUFA Date November 5 ..Next Hot Play guys
This Stock is one of the cheapest in the Biotech Sector . They have $45.7 M in Cash and a Market Cap of just $67 M thats ridiculous for a Company with such a Mega Pipeline .Another good sign is that Management bought 187k Shares in last few weeks .This is the Perfect time to load up before the speculators jumping in .
FDA decision on November 5 (Macrilen) and Interim Phase 3 results in 1H 2015 (ZoptEC) !
AEZS could run to $3-5 before FDA decision in early November .GL Aeterna Zentaris (AEZS)
Jun 10/14 Jun 10/14 Egbert, Carolyn Direct Ownership Common Shares 10 - Acquisition in the public market 100,000 $1.10 USD Apr 14/14 Apr 11/14 Dodd, David Alan Direct Ownership Common Shares 10 - Acquisition in the public market 87,000 $1.15 USD
•Filing of a New Drug Application ("NDA") seeking approval for the commercialization of MACRILEN™ as the firstavailable oral product indicated for the evaluation of Adult Growth Hormone Deficiency
. NDA currently undersubstantive review by the US Food and Drug Administration with a Prescription Drug User Fee Act date of November 5,2014
Zoptarelin doxorubicin
Operate trial in support of achieving first interim analysis for ZoptEC Phase 3 trial in H1-2015
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.